Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...
216 Views
Strike 2 in St Louis: Trump's Town Hall Trap
Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues....
206 Views
Takeda Pharmaceutical - Is M&A the Way Out of Its Problems?
The FT has reported that Takeda Pharmaceutical may be back on the acquisition trail, with a US$15bil war-chest. This puts into the public domain a...
197 Views
Allergan's Wide Moat Supports Industry-Leading Growth and Profit
Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook. We anticipate high-single-digit growth for...
248 Views
Our Ultimate Stock-Pickers Top 10 New-Money Purchases
Our early read on the buying and selling activity of our top managers during the second quarter uncovered a few nuggets. New-money purchases were...
164 Views